ADVAIR 250 AEROSOL, METERED DOSE

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

SALMETEROL (SALMETEROL XINAFOATE); FLUTICASONE PROPIONATE

Disponible desde:

GLAXOSMITHKLINE INC

Código ATC:

R03AK06

Designación común internacional (DCI):

SALMETEROL AND FLUTICASONE

Dosis:

25MCG; 250MCG

formulario farmacéutico:

AEROSOL, METERED DOSE

Composición:

SALMETEROL (SALMETEROL XINAFOATE) 25MCG; FLUTICASONE PROPIONATE 250MCG

Vía de administración:

INHALATION

Unidades en paquete:

120 DOSES

tipo de receta:

Prescription

Área terapéutica:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0238341006; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2001-12-21

Ficha técnica

_ _
_ _
_Page 1 of 70_
PR
ADVAIR DISKUS
fluticasone propionate and salmeterol inhalation powder USP
Pr
ADVAIR DISKUS _100_
100 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR DISKUS _250_
250 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR DISKUS _500_
500 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate
salt)
PR
ADVAIR
fluticasone propionate and salmeterol pressurised inhalation,
suspension BP
Pr
ADVAIR _125_
125 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate
salt)
Pr
ADVAIR _250_
250 mcg fluticasone propionate and 25 mcg salmeterol (as the xinafoate
salt)
Corticosteroid and Bronchodilator for Oral Inhalation
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
June 17, 2020
Submission Control No: 237271
_© 2020 GSK group of companies or its licensor_
Trademarks are owned by or licensed to the GSK group of companies.
_ _
_ _
_Page 2 of 70_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
3
SUMMARY
PRODUCT
INFORMATION
...............................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.....................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS
AND
PRECAUTIONS
........................................................................................................
4
ADVERSE
REACTIONS
........................................................................................................................
15
DRUG
INTERACTIONS
........................................................................................................................
24
DOSAGE
AND
ADMINISTRATION..........................................................................